Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

Ron L H Handels; Stephanie J B Vos; Milica G. Kramberger; Vesna Jelic; Kaj Blennow; Mark van Buchem; Wiesje van der Flier; Yvonne Freund-Levi; Harald Hampel; Marcel Olde Rikkert; Ania Oleksik; Zvezdan Pirtosek; Philip Scheltens; Hilkka Soininen; Charlotte Teunissen; Magda Tsolaki; Asa K. Wallin; Bengt Winblad; Frans R. J. Verhey; Pieter Jelle Visser

doi:10.1016/j.jalz.2016.12.015

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

Ron L H Handels, Stephanie J B Vos, Milica G. Kramberger, Vesna Jelic, Kaj Blennow, Mark van Buchem, Wiesje van der Flier, Yvonne Freund-Levi, Harald Hampel, Marcel Olde Rikkert, Ania Oleksik, Zvezdan Pirtosek, Philip Scheltens, Hilkka Soininen, Charlotte Teunissen, Magda Tsolaki, Asa K. Wallin, Bengt Winblad, Frans R. J. Verhey, Pieter Jelle Visser

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0-1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.

Original language	English
Pages (from-to)	903-912
Journal	Alzheimer's and Dementia
Volume	13
Issue number	8
DOIs	https://doi.org/10.1016/j.jalz.2016.12.015
Publication status	Published - 2017

Subject classification (UKÄ)

Geriatrics

Free keywords

Alzheimer's disease
Conversion
Dementia
Mild cognitive impairment
Predict
Prognosis
Progression
Reclassification
Risk
Risk prediction model

Access to Document

10.1016/j.jalz.2016.12.015

Cite this

Handels, R. L. H., Vos, S. J. B., Kramberger, M. G., Jelic, V., Blennow, K., van Buchem, M., van der Flier, W., Freund-Levi, Y., Hampel, H., Olde Rikkert, M., Oleksik, A., Pirtosek, Z., Scheltens, P., Soininen, H., Teunissen, C., Tsolaki, M., Wallin, A. K., Winblad, B., Verhey, F. R. J., & Visser, P. J. (2017). Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 13(8), 903-912. https://doi.org/10.1016/j.jalz.2016.12.015

@article{da6d3815008944aab3c4e7813f27b838,

title = "Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers",

abstract = "Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0-1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.",

keywords = "Alzheimer's disease, Conversion, Dementia, Mild cognitive impairment, Predict, Prognosis, Progression, Reclassification, Risk, Risk prediction model",

author = "Handels, {Ron L H} and Vos, {Stephanie J B} and Kramberger, {Milica G.} and Vesna Jelic and Kaj Blennow and {van Buchem}, Mark and {van der Flier}, Wiesje and Yvonne Freund-Levi and Harald Hampel and {Olde Rikkert}, Marcel and Ania Oleksik and Zvezdan Pirtosek and Philip Scheltens and Hilkka Soininen and Charlotte Teunissen and Magda Tsolaki and Wallin, {Asa K.} and Bengt Winblad and Verhey, {Frans R. J.} and Visser, {Pieter Jelle}",

year = "2017",

doi = "10.1016/j.jalz.2016.12.015",

language = "English",

volume = "13",

pages = "903--912",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Wiley",

number = "8",

}

Handels, RLH, Vos, SJB, Kramberger, MG, Jelic, V, Blennow, K, van Buchem, M, van der Flier, W, Freund-Levi, Y, Hampel, H, Olde Rikkert, M, Oleksik, A, Pirtosek, Z, Scheltens, P, Soininen, H, Teunissen, C, Tsolaki, M, Wallin, AK, Winblad, B, Verhey, FRJ & Visser, PJ 2017, 'Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers', Alzheimer's and Dementia, vol. 13, no. 8, pp. 903-912. https://doi.org/10.1016/j.jalz.2016.12.015

TY - JOUR

T1 - Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

AU - Handels, Ron L H

AU - Vos, Stephanie J B

AU - Kramberger, Milica G.

AU - Jelic, Vesna

AU - Blennow, Kaj

AU - van Buchem, Mark

AU - van der Flier, Wiesje

AU - Freund-Levi, Yvonne

AU - Hampel, Harald

AU - Olde Rikkert, Marcel

AU - Oleksik, Ania

AU - Pirtosek, Zvezdan

AU - Scheltens, Philip

AU - Soininen, Hilkka

AU - Teunissen, Charlotte

AU - Tsolaki, Magda

AU - Wallin, Asa K.

AU - Winblad, Bengt

AU - Verhey, Frans R. J.

AU - Visser, Pieter Jelle

PY - 2017

Y1 - 2017

N2 - Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0-1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.

AB - Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0-1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.

KW - Alzheimer's disease

KW - Conversion

KW - Dementia

KW - Mild cognitive impairment

KW - Predict

KW - Prognosis

KW - Progression

KW - Reclassification

KW - Risk

KW - Risk prediction model

UR - http://www.scopus.com/inward/record.url?scp=85014793039&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.12.015

DO - 10.1016/j.jalz.2016.12.015

M3 - Article

C2 - 28216393

AN - SCOPUS:85014793039

SN - 1552-5260

VL - 13

SP - 903

EP - 912

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 8

ER -

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

Abstract

Subject classification (UKÄ)

Free keywords

Access to Document

Other files and links

Fingerprint

Cite this